Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
暂无分享,去创建一个
Jacques P. Brown | T. Schnitzer | J. Block | J. Kaufman | M. Nevitt | P. Delmas | J. Rodriguez-Portales | K. Saag | J. Sharp | C. Menkes | N. Lane | J. Adachi | U. Liberman | M. Malice | R. Westhovens | E. Seeman | J. Melo-Gomes | R. Correa-Rotter | K. Siminoski | P. Poubelle | Jean Kaufman | F. Hawkins | W. Carofano | A. Daifotis | B. Gruber | T. Dumortier | J. Wing | M. Leite | R. Emkey | H. Mcilwain | M. Czachur | J. Brown | M. Yanover | M. Malice | J. Wing | B. Gruber | J. A. Rodriguez-Portales | H. McIlwain | Maria Odette R. Leite
[1] M. Hochberg,et al. Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .
[2] S. Wallach,et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.
[3] D. Felsenberg,et al. Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.
[4] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[5] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[6] C. Roux,et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. , 1998, The Journal of clinical endocrinology and metabolism.
[7] P. Rottoli,et al. Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients , 1997, Calcified Tissue International.
[8] Jacques P. Brown,et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.
[9] Ego Seeman,et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.
[10] E. Themeles,et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. , 1997, British journal of rheumatology.
[11] E. Leib,et al. Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis , 1996, Annals of Internal Medicine.
[12] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[13] M. Pringle,et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study , 1996, BMJ.
[14] S. Cummings,et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .
[15] B. Dijkmans,et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. , 1996, Arthritis and rheumatism.
[16] M. Krogsgaard,et al. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. , 1996, Annals of the rheumatic diseases.
[17] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[18] C. Cooper,et al. Rheumatoid arthritis, corticosteroid therapy and hip fracture. , 1995, Annals of the rheumatic diseases.
[19] T. Spector,et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. , 1994, Arthritis and rheumatism.
[20] D. Furst,et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.
[21] D. Boumpas,et al. Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.
[22] J. Eisman,et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. , 1993, The New England journal of medicine.
[23] Joseph F. Heyse,et al. An Empirical and Simulated Comparison of Some Tests for Detecting Progressiveness of Response with Increasing Doses of a Compound , 1992 .
[24] L. Raisz,et al. Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.
[25] I. Reid,et al. PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD) , 1988, The Lancet.
[26] H K Genant,et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? , 1985, Arthritis and rheumatism.
[27] J W Tukey,et al. Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.